On or before December 31, 2021, the Board, in consultation with the Stakeholder Council, shall:
(1) Study:
(i) The entire pharmaceutical distribution and payment system in the State; and
(ii) Policy options being used in other states and countries to lower the list price of pharmaceuticals, including:
1. Setting upper payment limits;
2. Using a reverse auction marketplace; and
3. Implementing a bulk purchasing process; and
(2) Report its findings and recommendations, including findings for each option studied under item (1)(ii) of this section and any legislation required to implement the recommendations, to the Senate Finance Committee and the House Health and Government Operations Committee in accordance with § 2–1257 of the State Government Article.
Structure Maryland Statutes
Title 21 - Food, Drugs, and Cosmetics
Subtitle 2C - Prescription Drug Affordability Board
Section 21-2C-01 - Definitions
Section 21-2C-02 - Prescription Drug Affordability Board
Section 21-2C-04 - Prescription Drug Affordability Stakeholder Council
Section 21-2C-05 - Disclosure of Conflicts of Interest
Section 21-2C-06 - Acceptance of Gratuities Prohibited
Section 21-2C-08 - Collection, Review, and Use of Transparency Data for Prescription Drug Products
Section 21-2C-09 - Cost Review of Prescription Drug Products With Affordability Challenges
Section 21-2C-10 - Confidentiality
Section 21-2C-11 - Funding Source
Section 21-2C-12 - Enforcement
Section 21-2C-14 - Setting Upper Payment Limits for Prescription Drug Products